Sort
50,496 grants matching “lung cancer”
Novel Perceptual and Oculomotor Heuristics for Enhancing Radiologic Performance
$555,354Susana Martinez-Conde · Suny Downstate Medical Center · R01 · FY2025 · CA
Personalized Task-Based Respiratory Motion Correction for Low-Dose PET/CT
$555,311Chi Liu · Yale University · R01 · FY2020 · CA
Therapy for Metastatic breast cancer based on micro RNA silencing
$555,309Anna Moore · Michigan State University · R01 · FY2022 · CA
Discovery and development of Ku-targeted small molecule inhibitors: A novel mechanism of DNA-PK inhibition
$555,248John J Turchi · Indiana University Indianapolis · R01 · FY2024 · CA
ULTRASENSITIVE DETECTION OF SUBCLINICAL LUNG CANCER BY STATISTICAL ANALYSIS OF PLASMA CFDNA-DERIVED WHOLE-GENOME SEQUENCING DATA
$555,216Dana-Farber Cancer Institute, Inc. · · FY2018 · Department of the Army
Chemoprevention of Tobacco Related Cancer in Animals
$555,139Ohio State University · R01 · FY2003 · CA
Role of Protein Scaffolds in RTK-Ras-dependent Signal Transduction
$555,132Deborah Morrison · Division Of Basic Sciences - Nci · ZIA · FY2017 · CA
Mechanisms of resistance to ponatinib therapy in chronic myeloid leukemia
$555,104Thomas J. O'Hare · University Of Utah · R01 · FY2016 · CA
Investigating Max as a tumor suppressor gene in small cell lung cancer and other neuroendocrine tumors
$555,102Robert Neil Eisenman · Fred Hutchinson Cancer Research Center · R01 · FY2020 · CA
15-Hydroxyprostaglandin Dehydrogenase, NSAIDs, Vitamin D, and Coloretcal Neoplasi
$554,959Li Li · Case Western Reserve University · U01 · FY2016 · CA
UCHL1 IS A NOVEL MINIMALLY INVASIVE MOLECULAR INDICATOR AND THERAPEUTIC TARGET FOR SMALL CELL LUNG CANCER
$554,904University Of California, Los Angeles · · FY2025 · Defense Health Agency
Synthetic Lethal Targeting of SETD2 in Renal Cell Carcinoma
$554,891Keith D Robertson · Mayo Clinic Rochester · R01 · FY2023 · CA
Genomics and Functional Characterization of NF1-mutated Lung Cancer
$554,851Eric Collisson · University Of California, San Francisco · R01 · FY2018 · CA
(8) Mechanisms of autoimmune endocrine diseases in patients receiving checkpoint inhibitors
$554,845Kevan C Herold · Yale University · R01 · FY2022 · CA
High-Throughput Screening and Validation of Molecular Targeted Chemoradiosensitizers
$554,744Henning Willers · Massachusetts General Hospital · U01 · FY2022 · CA
Validation of Biomarkers of Risk for the Early Detection of Lung Cancer
$554,708Eric L Grogan · Vanderbilt University Medical Center · U01 · FY2021 · CA
[18F]ALPHAVBETA6-BINDING PEPTIDE POSITRON EMISSION TOMOGRAPHY FOR STAGING, RESPONSE ASSESSMENT, AND PATIENT SELECTION IN METASTATIC NON-SMALL CELL LUNG CANCER
$554,584University Of California, Davis · · FY2020 · Defense Health Agency
Using SMART Design to Improve Symptom Management Strategies Among Cancer Patients
$554,574Gwen Karilyn Wyatt · Michigan State University · R01 · FY2018 · CA
Role of Novel Cytokine-like Molecule Secretoglobin (SCGB) 3A2 in Lung
$554,547Shioko Kimura · Division Of Basic Sciences - Nci · ZIA · FY2025 · CA
The Impact of Tobacco Control Policies on Health Equity in the United States
$554,510Nancy Fleischer · University Of Michigan At Ann Arbor · R37 · FY2020 · CA
Maladaptive epigenetic control of MUC5B transcription in pulmonary fibrosis
$554,488Anthony N Gerber · University Of Colorado Denver · P01 · FY2024 · HL
Personalizing NSCLC Therapy: Exploiting KRAS activated pathways
$554,459Roy S Herbst · Yale University · R01 · FY2015 · CA
A Quantitative Multiplexed Platform for the Pharmacogenomic Analysis of Lung Cancer
$554,387Monte Meier Winslow · Stanford University · R01 · FY2017 · CA
A Quantitative Multiplexed Platform for the Pharmacogenomic Analysis of Lung Cancer
$554,387Monte Meier Winslow · Stanford University · R01 · FY2016 · CA
A Quantitative Multiplexed Platform for the Pharmacogenomic Analysis of Lung Cancer
$554,387Monte Meier Winslow · Stanford University · R01 · FY2018 · CA